Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 18/20 | 0.76 |
| ▸ | DGKZ | Q13574 | 18/20 | 0.76 |
| ▸ | DGKI | O75912 | 3/20 | 0.76 |
| ▸ | DGKG | P49619 | 2/20 | 0.76 |
| ▸ | DGKB | Q9Y6T7 | 2/20 | 0.76 |
| ▸ | DGKK | Q5KSL6 | 1/20 | 0.76 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23293461 | 1.00 | DGKA (0.76) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293193 | 0.94 | DGKA (0.79) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL30616406 | 0.94 | DGKA (0.79) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL30616404 | 0.92 | DGKZ (0.67) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293410 | 0.92 | DGKZ (0.67) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293427 | 0.91 | DGKA (0.64) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293504 | 0.91 | DGKA (0.64) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293219 | 0.91 | DGKA (0.65) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293421 | 0.91 | DGKZ (0.65) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293208 | 0.90 | DGKZ (0.62) | DGKADGKZDGKIDGKGDGKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | claimed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |